title: [MGMT analysis in gliomas].
abstract: MGMT status is now regarded as a strong predictive factor of response to standard treatment of newly diagnosed glioblastomas involving temozolomide (TMZ) and radiotherapy. MGMT promoter methylation is also a prognostic factor - independent of treatment - in anaplastic gliomas. The predictive function can be explained by the role of the DNA repair enzyme MGMT, which antagonizes the effects of alkylating agents such as TMZ. MGMT promoter methylation could also reflect a particular molecular phenotype with its own specific prognostic significance. Since MGMT status determination is becoming a crucial biological marker in new clinical glioma trials, and is beginning to be used in day-to-day clinical practice, there is currently a strong need to determine the best technique for MGMT analysis. A French multicenter study has been set up for this purpose.
authors: CRLCC Eugène-Marquis, Rennes, France. v.quillien@rennes.fnclcc.fr
authors: Véronique
authors: V
authors: Quillien
authors: Elodie
authors: E
authors: Vauléon
authors: Stephan
authors: S
authors: Saikali
authors: Thierry
authors: T
authors: Lesimple
authors: Abderrahmane
authors: A
authors: Hamlat
authors: Amandine
authors: A
authors: Etcheverry
authors: Jean
authors: J
authors: Mosser
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000201:enzymology; D004260:DNA Repair; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics / Q000502:physiology; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000032:analysis* / Q000235:genetics / Q000502:physiology; D011379:Prognosis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009363:Neoplasm Proteins; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D000077204:Temozolomide